קיוביצין 500 מ"ג

Country: Iżrael

Lingwa: Ebrajk

Sors: Ministry of Health

Ingredjent attiv:

DAPTOMYCIN 500 MG/VIAL

Disponibbli minn:

MEDISON PHARMA LTD

Kodiċi ATC:

J01XX09

Għamla farmaċewtika:

LYOPHILIZED POWDER FOR INJECTION

Rotta amministrattiva:

I.V

Manifatturat minn:

CUBIST PHARMACEUTICALS INC, USA

Grupp terapewtiku:

DAPTOMYCIN

Indikazzjonijiet terapewtiċi:

Cubicin (daptomycin for injection) is indicated for the treatment of complicated skin and skin structure infections caused by susceptible strains of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant strains) Streptococcus pyogenes Streptococcus agalactiae Streptococcus dysgalactiae subsp. equisimilis and Enterococcus faecalis (vancomycin-susceptible strains only). Combination therapy may be clinically indicated if the documented or presumed pathogens include Gram-negative or anaerobic organisms. Daptomycin is not indicated for the treatment of pneumonia. Appropriate specimens for microbiological examination should be obtained in order to isolate and identify the causative pathogens and to determine their susceptibility to daptomycin. Empiric therapy may be initiated while awaiting test results. Antimicrobial therapy should be adjusted as needed based upon test results. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cubici

Data ta 'l-awtorizzazzjoni:

2009-06-01